Lord, Abbett & Co
PTCT icon

Lord, Abbett & Co’s PTC Therapeutics PTCT Stock Holding History

Lord, Abbett & Co’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.1M Sell
590,074
-27,047
-4% -$1.95M 0.14% 188
2026
Q1 		$42M Sell
617,121
-9,985
-2% -$707K 0.14% 181
2025
Q4 		$47.6M Buy
627,106
+249,053
+66% +$18.1M 0.15% 173
2025
Q3 		$23.2M Sell
378,053
-6,394
-2% -$333K 0.07% 266
2025
Q2 		$18.8M Buy
+384,447
New +$18.3M 0.06% 296
2020
Q3 		– Sell
-236,212
Closed -$12M – 672
2020
Q2 		$12M Sell
236,212
-14,995
-6% -$737K 0.04% 453
2020
Q1 		$11.2M Buy
+251,207
New +$12.6M 0.05% 411
2015
Q3 		– Sell
-191,912
Closed -$9.24M – 951
2015
Q2 		$9.24M Sell
191,912
-108,183
-36% -$6.31M 0.02% 655
2015
Q1 		$18.3M Buy
300,095
+177,500
+145% +$10.8M 0.05% 504
2014
Q4 		$6.35M Sell
122,595
-30,012
-20% -$1.32M 0.02% 690
2014
Q3 		$6.72M Buy
+152,607
New +$4.77M 0.02% 679

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Lord, Abbett & Co's PTCT Position: Q2 2026 in Review

Lord, Abbett & Co reduced its PTC Therapeutics (PTCT) stake by 4.4% in Q2 2026, selling an estimated $1.95M and leaving 590,074 shares worth $48.1M. The position accounts for 0.14% of the portfolio, ranked #188.

Lord, Abbett & Co first reported a position in PTCT in Q3 2014 and has held it in 11 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Lord, Abbett & Co held 590,074 shares of PTC Therapeutics worth $48.1M as of Q2 2026.
  • Lord, Abbett & Co sold 27,047 PTC Therapeutics shares in Q2 2026, an estimated $1.95M.
  • PTC Therapeutics made up 0.14% of Lord, Abbett & Co's portfolio in Q2 2026, its #188 holding.
  • Lord, Abbett & Co first reported a position in PTC Therapeutics in Q3 2014 and has held it in 11 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.